A phase II study of sequential velcade/thalidomide/dexamethasone as maintenance therapy post single autologous peripheral stem cell in patients with multiple myeloma

被引：0
|
作者：
Sahebi, F. [1 ]
机构：
[1] City Hope Natl Med Ctr, Duarte, CA 91010 USA
来源：
BONE MARROW TRANSPLANTATION | 2010年 / 45卷
关键词：
D O I：
暂无
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
引用
收藏
页码：S148 / S148
页数：1
相关论文
共 50 条
  • [1] A Phase II Study of Sequential Velcade/Thalidomide/Dexamethasone (VTD) as Maintenance Therapy Post Single Autologous Peripheral Stem Cell (PSCT) in Patients with Multiple Myeloma
    Sahebi, Firoozeh
    Krishnan, Amrita
    Somlo, George
    Popplewell, Leslie
    Parker, P.
    Cai, Ji-Lian
    Farol, Len
    Spielberger, Ricardo
    Kogut, Neil Martin
    Karanes, Chatchada
    Ruel, Christopher
    Frankel, Paul
    Arceo, Fermin
    Duarte, Lupe
    O'Donnell, Margaret
    Forman, Stephen J.
    BLOOD, 2009, 114 (22) : 1321 - 1322
  • [2] Sequential Bortezomib, Dexamethasone, and Thalidomide Maintenance Therapy after Single Autologous Peripheral Stem Cell Transplantation in Patients with Multiple Myeloma
    Sahebi, Firoozeh
    Frankel, Paul H.
    Farol, Len
    Krishnan, Amrita Y.
    Cai, Ji-lian
    Somlo, George
    Thomas, Sandra H.
    Reburiano, Eunicia
    Popplewell, Leslie L.
    Parker, Pablo M.
    Spielberger, Ricardo T.
    Karanes, Chatchada
    Htut, Myo
    Ruel, Christopher
    Duarte, Lupe
    Murata-Collins, Joyce L.
    Forman, Stephen J.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2012, 18 (03) : 486 - 492
  • [3] Sequential VAD (vincristine, adriamycin, dexamethasone) and VTD (VELCADE®, thalidomide, dexamethasone) induction followed by high-dose therapy with autologous stem cell transplantation and maintenance treatment with VELCADE for newly diagnosed multiple myeloma:: Interim results of phase II trial
    Yoon, Sung-Soo
    Kim, Hye Jin
    Lee, Dong Soon
    Eom, Hyeon Seok
    Jang, Jun Ho
    Chung, Ju Seup
    Kang, Hye Jin
    Kim, Cheol Soo
    Kim, Kihyun
    Lee, Jae Hoon
    Lee, Sang Jae
    Min, Yu Hong
    Seong, Chu Myong
    Sohn, Sang Kyun
    Suh, Cheolwon
    Won, Jong Ho
    BLOOD, 2007, 110 (11) : 290A - 290A
  • [4] Thalidomide/dexamethasone (TD), bortezomib (Velcade)/thalidomide/dexamethasone (VTD) and VBMCP/VBAD/Velcade as induction therapy prior to high-dose therapy/autologous stem cell transplantation in multiple myeloma
    Rosinol, L.
    Cibeira, M. T.
    Martinez, J.
    Mateos, M. V.
    Oriol, A.
    Terol, M. J.
    Garcia-Larana, J.
    Hernandez, D.
    de la Rubia, J.
    Sureda, A.
    Besalduch, J.
    Palomera, L.
    Gonzalez, Y.
    Echebeste, M. A.
    Diaz-Mediavilla, J.
    de Arriba, F.
    Alegre, A.
    Hernandez, M.
    Lahuerta, J. J.
    Miguel, J. F. San
    Blade, J.
    BONE MARROW TRANSPLANTATION, 2010, 45 : S18 - S18
  • [5] Maintenance thalidomide following single cycle autologous peripheral blood stem cell transplant in patients with multiple myeloma
    Sahebi, F
    Spielberger, R
    Kogut, NM
    Fung, H
    Falk, PM
    Parker, P
    Krishnan, A
    Rodriguez, R
    Nakamura, R
    Nademanee, A
    Popplewell, L
    Frankel, P
    Ruel, C
    Tin, R
    Ilieva, P
    Forman, SJ
    Somlo, G
    BONE MARROW TRANSPLANTATION, 2006, 37 (09) : 825 - 829
  • [6] Maintenance thalidomide following single cycle autologous peripheral blood stem cell transplant in patients with multiple myeloma
    F Sahebi
    R Spielberger
    N M Kogut
    H Fung
    P M Falk
    P Parker
    A Krishnan
    R Rodriguez
    R Nakamura
    A Nademanee
    L Popplewell
    P Frankel
    C Ruel
    R Tin
    P Ilieva
    S J Forman
    G Somlo
    Bone Marrow Transplantation, 2006, 37 : 825 - 829
  • [7] Thalidomide as maintenance therapy following double cycle autologous peripheral blood stem cell transplant in patients with multiple myeloma
    Pratico, G.
    Martino, M.
    Console, G.
    Irrera, G.
    Mesina, G.
    Callea, V
    Stelitano, C.
    Molica, S.
    Morabito, F.
    Piro, E.
    Quartarone, E.
    Musolino, C.
    Mamone, D.
    Iacopino, P.
    ANNALS OF ONCOLOGY, 2006, 17 : XI57 - XI57
  • [8] Phase II Study Of The Combination Of MLN 9708 With Lenalidomide As Maintenance Therapy Post Autologous Stem Cell Transplant In Patients With Multiple Myeloma
    Shah, Jatin J.
    Baladandayuthapani, Veera
    Weber, Donna M.
    Thomas, Sheeba K.
    Alexanian, Raymond
    Wang, Michael
    Qazilbash, Muzaffar H.
    Champlin, Richard E.
    Shah, Nina
    Bashir, Qaiser
    Popat, Uday R.
    Nieto, Yago
    Ahmed, Sairah
    Parmar, Simrit
    Orlowski, Robert Z.
    BLOOD, 2013, 122 (21)
  • [9] Sequential VAD (vincriestine, adriamycin, dexamethasone) and VTD (velcade, thalidomide, dexamethasone) induction followed by high-dose therapy with autologous stem cell transplantation and maintenance treatment with velcade for newly diagnosed multiple myeloma: Preliminary analysis of efficacy and safety
    Yoon, S. S.
    Kim, H. J.
    Lee, D. S.
    Lee, S. J.
    Seong, J. M.
    Suh, C.
    Kim, K.
    Eom, H. S.
    Min, Y. H.
    Jung, J. S.
    Kim, C. S.
    Kang, H. J.
    Jang, J. H.
    Lee, J. H.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 (06): : 182 - 182
  • [10] Sequential treatment with bortezomib plus thalidomide plus dexamethasone followed by autologous hematopoietic stem cell transplantation (HSCT); consolidation and maintenance therapy in patients with multiple myeloma
    Bachiri, A.
    Bekadja, M. A.
    Talhi, S.
    Abderrahmani, S.
    Ouldjeriouat, H.
    Bouhass, R.
    BONE MARROW TRANSPLANTATION, 2017, 52 : S509 - S509
12345